Treatment
PD-1 inhibitor clinical trials
We’re tracking 200 recruiting studies that include PD-1 inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT07041320Recruiting
Oral chemo and immunotherapy for older adults with lung cancer
This trial is testing a combination of an oral chemotherapy pill (vinorelbine) and an immunotherapy drug (PD-1 inhibitor) for people aged 65 and older with advanced non-small cell lung cancer who have not had treatment before. The goal is to see if this approach can help control the cancer with fewer side effects.
Hefei, AnhuiAges 65 years+ - NCT07077512RecruitingPhase 2
CAR-T cells plus immunotherapy for advanced B-cell lymphoma
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
GuangzhouAges 18–70 - NCT07277439RecruitingPhase 2
Immunotherapy and chemoradiation before surgery for stomach cancer
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07282184RecruitingPhase 1/Phase 2
Liver cancer risk prediction and treatment study
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
Wuhan, HubeiAges 18–75 - NCT07285395RecruitingPhase 1
Study of AT1019 with radiation and immunotherapy for advanced solid tumors
This trial tests a new drug called AT1019 given together with targeted radiation (SBRT) and an immunotherapy drug for people with advanced solid tumors that are already being treated with immunotherapy. It aims to see if this combination can shrink or control tumors better.
Xuzhou, JiangsuAges 18 years+ - NCT07332247RecruitingPhase 2
Immunotherapy plus chemo then immediate vs selective re-radiation for advanced recurrent NPC
This trial is for people with nasopharyngeal cancer that has come back in the same area. It tests whether giving additional radiation right after chemo plus immunotherapy works better than waiting to see if more radiation is needed later.
Guangzhou, GuangdongAges 18–70 - NCT07337096Recruiting
Electro-acupuncture for advanced lung cancer: the EALER study
This study tests whether adding electro-acupuncture (a gentle type of acupuncture with mild electrical pulses) to standard first-line immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer. It aims to see if this combination improves quality of life and overall treatment outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07387198RecruitingPhase 2
Testing cemiplimab before surgery for Merkel cell carcinoma
This trial tests whether giving the immunotherapy drug cemiplimab before surgery can improve outcomes for people with stage I or II Merkel cell carcinoma. If you qualify, you would receive cemiplimab before your sentinel lymph node biopsy.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT07394387RecruitingPhase 2
HIFU with or without immunotherapy before chemo for triple-negative breast cancer
This trial tests whether adding focused ultrasound (HIFU) and an immunotherapy drug (PD-1 inhibitor) before standard chemotherapy can improve outcomes for women with stage II or III triple-negative breast cancer (TNBC). It aims to find a more effective way to shrink tumors before surgery.
Nanjing, JiangsuAges 18–70 - NCT07401199Recruiting
AI predicts immunotherapy response in advanced stomach cancer
This trial uses artificial intelligence to analyze CT scans, blood, and tumor tissue to predict how well your cancer will respond to chemotherapy and immunotherapy before surgery. It aims to personalize treatment for locally advanced stomach or gastroesophageal junction cancer.
Fuyang, AnhuiAges 18 years+ - NCT07495215RecruitingPhase 1/Phase 2
Personalized mRNA vaccine plus immunotherapy for liver cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
Hangzhou, ZhejiangAges 18–75 - NCT07519486RecruitingPhase 2
Nutrition support during cancer treatment before surgery
This trial tests whether intensive nutritional support helps patients with advanced esophageal cancer (a type of squamous cell carcinoma) respond better to treatment before surgery. The goal is to improve how well the cancer shrinks and prepare the body for a successful operation.
Chengdu, SichuanAges 18–80 - NCT07590024RecruitingPhase 3
Personalized Cancer Treatment Guidance for Nasopharyngeal Cancer
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
Beijing, Beijing MunicipalityAges 18–65 - NCT07618078Recruiting
Personalized Cancer Risk Assessment for Nasopharyngeal Cancer
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
Beijing, Beijing MunicipalityAges 18–75 - NCT07669220RecruitingPhase 2
Short radiation, immunotherapy, and chemo for advanced rectal cancer
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
GuangzhouAges 18–75 - NCT07339488RecruitingPhase 2
Low-dose radiation plus immunotherapy to shrink esophageal cancer before surgery
This trial tests whether a combination of low-dose radiation and immunotherapy can shrink advanced esophageal cancer enough to make it removable by surgery. It is for people whose cancer is considered borderline resectable or unresectable due to its location or spread.
Shantou, GuangdongAges 18–75 - NCT07754812RecruitingPhase 4
Oral paclitaxel with immunotherapy and SBRT before surgery for older adults with lung cancer
This trial tests a new way to treat non-small cell lung cancer in people aged 70 or older. You will receive oral chemotherapy (paclitaxel) with immunotherapy and focused radiation (SBRT) before surgery, hoping to shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 70 years+ - NCT04966481RecruitingPhase 3
Palbociclib plus cetuximab versus cetuximab alone
This trial studies whether adding palbociclib to cetuximab works better than cetuximab by itself for head and neck cancer that is growing again after an anti–PD-1/PD-L1 treatment. It is for people whose tumor has a specific gene change (CDKN2A loss) and who have not had too many prior treatments.
Worthington, MinnesotaAges 18 years+ - NCT05978102RecruitingPhase 1/Phase 2
Study of STI-7349 for advanced solid cancers
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
Yiwu, ZhejiangAges 18–80 - NCT06430437RecruitingPhase 3
Study of SHR-A1811 for first-line treatment of advanced lung cancer with HER2 mutations
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07652125Recruiting
RGL-270 vaccine plus immunotherapy for advanced lung cancer
This trial tests a new cancer vaccine (RGL-270) combined with immunotherapy drugs for advanced non-small cell lung cancer. The vaccine is designed to train your immune system to recognize and fight your specific cancer.
Guangzhou, Other (Non U.s.)Ages 18 years+ - NCT06214143RecruitingPhase 1/Phase 2
T3011 plus immunotherapy for advanced solid tumors
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
AnyangAges 18 years+ - NCT04615988Recruiting
Vitamin D levels and hormone side effects from immune cancer therapy
This study looks at whether your blood vitamin D level is linked to hormone-related side effects caused by immune checkpoint cancer drugs. It may help doctors better predict who is at risk and how to monitor patients during treatment.
New York, New YorkAges 18 years+ - NCT06313541RecruitingPhase 2
Adaptive radiation with immunotherapy for advanced lung cancer
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
ShanghaiAges 18 years+
Common questions
- Are there clinical trials studying PD-1 inhibitor?
- Yes. Clin2 currently lists 200 recruiting studies that include PD-1 inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a PD-1 inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is PD-1 inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether PD-1 inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.